Medicaid Pharmacy and Therapeutics Committee Agenda for December 13, 2007

The Pharmacy & Therapeutics Committee will meet December 13, 2007, from 8:45 a.m. to 3:45 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items

1. Review of the Growth Hormone therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Genotropin (somatropin), Humatrope (somatropin), Norditropin (somatropin), Nutropin (somatropin), Omnitrope (somatropin), Saizen (somatropin), Tev-Tropin (somatropin), Zorbtive (somatropin)

2. Review of the Erythropoiesis Stimulating Agent (ESA) therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Procrit (epoetin alfa)

3. Review of the Progestin (for Cachexia) therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: megestrol acetate, Megace (megestrol acetate), Megace ES (megestrol acetate)

4. Review of the Carbamazepine Derivative therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: carbamazepine, Carbatrol (carbamazepine ER), Epitol (carbamazepine), Equetro (carbamazepine ER), oxcarbazepine, Tegretol (carbamazepine), Tegretol XR (carbamazepine ER), Trileptal (oxcarbazepine)

5. Review of the Ophthalmic Non-Steroidal Anti-Inflammatory Drug (NSAID) therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Acular (ketorolac), Acular LS (ketorolac), Acular PF (ketorolac), flurbiprofen, Nevanac (nepafenac), Ocufen (flurbiprofen), Voltaren (diclofenac), Xibrom (bromfenac)

6. Review of the Ophthalmic Alpha-2 Adrenergic Agonist (for Glaucoma) therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Alphagan P (brimonidine), brimonidine, Iopidine (apraclonidine)

Agenda Timeline (subject to change based on meeting proceedings)

Time Agenda
8:45 - 9:00 Welcome and Introductions
9:00 - 10:00 Public Comments from interested parties *
10:00 - 10:15 Break
10:15 - 10:45 Clinical Review of Growth Hormones
10:45 - 11:15 Clinical Review of ESAs
11:15 - 11:45 Clinical Review of Progestins
11:45 - 1:00 Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
1:00 - 1:15 Final Recommendations for Preferred Drugs
1:15 - 1:45 Clinical Review of Carbamazepine Derivatives
1:45 - 2:15 Clinical Review of Ophthalmic NSAIDs
2:15 - 2:45 Clinical Review of Alpha-2 Adrenergics
2:45 - 3:15 Break/Executive Session (evaluation of trade secret supplemental rebate information)
3:15 - 3:30 Final Recommendations for Preferred Drugs
3:30 - 3:45 DOH Update, Final Comments and Adjournment

* Interested parties must notify DOH at least 1 week in advance of their request to speak during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. All written comments regarding topics before the Committee must be received at least 1 week in advance of the meeting. Written comments should summarize key points and may not exceed two (2) pages in length.

NOTE: Those wishing to submit clinical studies or clinical reports, rather than comments, must submit the study/report at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material.

Posted November 13, 2007